|
Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine. |
100.00% |
|
3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue. |
100.00% |
|
Deuterium Depletion Inhibits Cell Proliferation, RNA and Nuclear Membrane Turnover to Enhance Survival in Pancreatic Cancer |
100.00% |
|
A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gal |
100.00% |
|
Psorinum therapy in treating stomach, gall bladder, pancreatic, and liver cancers: a prospective clinical study. |
100.00% |
|
Bio-Immune therapy according to Professor Thomas Tallberg, a cure for Melanoma? |
97.50% |
|
Ukrain (NSC-631570) in the treatment of pancreas cancer. |
95.00% |
|
Psorinum, the anti cancer miracle from India. |
91.47% |
|
Clinical Investigations on Ukrain |
90.00% |
|
Dendritic cell-based vaccination in combination with gemcitabine/S-1 in patients with advanced pancreatic cancer. Sub-category: |
90.00% |
|
The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alp |
90.00% |
|
Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. |
90.00% |
|
A homeopathic approach to treat patients with advanced gallbladder, periampullary, and liver carcinomas: a report of 3 cases. |
90.00% |
|
Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins. |
90.00% |
|
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors. |
90.00% |
|
Opioid growth factor and the treatment of human pancreatic cancer: a review. |
90.00% |
|
NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell |
90.00% |
|
Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. |
90.00% |
|
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. |
90.00% |
|
Treatment of advanced pancreatic cancer with opioid growth factor: phase I. |
90.00% |
|
Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic ca |
90.00% |
|
71 year old woman, Pancraetic cancer with liver and lung metastasis. |
90.00% |
|
Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer. |
90.00% |
|
GcMAF-The cancer revolution from Japan |
87.50% |
|
NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial |
85.00% |
|
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growt |
80.00% |
|
Sanguinarine induces apoptosis of human pancreatic carcinoma AsPC-1 and BxPC-3 cells via modulations in Bcl-2 family proteins |
80.00% |
|
Alternative Cancer Treatment (interview with Dr. Gonzalez by Dr. Mercola) |
80.00% |
|
Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expressio |
80.00% |
|
Effect of emodin combined gemcitabine on the growth and apoptosis of pancreatic cancer cell line BxPC-3 in vitro |
80.00% |
|
A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. |
80.00% |
|
Treatment of locally advanced pancreatic cancer with concurrent uftoral and radiotherapy. Results from 64 patients treated from |
80.00% |
|
Metformin in the treatment of Cancer |
77.00% |
|
Cancer Psychotherapy according to Dr. Frederick B Levenson |
76.00% |
|
Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors. |
70.00% |
|
Anticancer Effect of Dihydroartemisinin (DHA) in a Pancreatic Tumor Model Evaluated by Conventional Methods and Optical Imaging. |
70.00% |
|
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer |
70.00% |
|
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer |
70.00% |
|
Efficacy of ukrain in the treatment of pancreatic cancer. |
70.00% |
|
Sorafenib and radiation: A promising combination in colorectal and pancreas cancer |
70.00% |
|
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. |
70.00% |
|
Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. |
70.00% |
|
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. |
70.00% |
|
Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma. |
70.00% |
|
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses |
70.00% |
|
Therapeutic vaccination against advanced pancreatic cancer by autologous dendritic cells pulsed with a MUC1 peptide: Preclinic.. |
60.00% |
|
Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo |
60.00% |
|
Survivin and pancreatic cancer. |
60.00% |
|
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors. |
60.00% |
|
A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients wi |
60.00% |
|
Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". |
60.00% |
|
Tissue factor, angiogenesis and thrombosis in pancreatic cancer. |
60.00% |
|
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symp |
60.00% |
|
Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. |
55.00% |
|
Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment? |
50.00% |
|
Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. |
50.00% |
|
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. |
50.00% |
|
Serum cytokines in pancreatic cancer: Correlation with outcome |
40.00% |
|
Phase I trial of capecitabine (Cap) and gemcitabine (G) with concurrent radical radiotherapy in locally advanced pancreatic ca.. |
40.00% |
|
Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic |
40.00% |
|
Inhibition of MIF Leads to Cell Cycle Arrest and Apoptosis in Pancreatic Cancer Cells. |
40.00% |
|
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer. |
40.00% |
|
Final analysis of a multicenter, randomized phase II trial comparing three different chemoradiotherapy regimens in the treatment |
30.00% |
|
Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. |
30.00% |
|
Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer. |
20.00% |
|
Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carci |
|
